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Objective: (1) To determine associations between radiographic features of lumbosacral (LS) spine disc
space narrowing (DSN) and osteophytes (OST) and joint metabolism biomarkers (serum cartilage olig-
omeric matrix protein (COMP), hyaluronic acid (HA), collagen neoepitope (C2C), C-propeptide of type II
procollagen (CP-II), urine C-terminal cross-linking telopeptide (CTX-II) and N-terminal telopeptide
(NTX-I)). (2) To explore interactions with race, gender and low back symptoms.
Design: Cross-sectional analysis of 547 participants enrolled in the Johnston County (JoCo) Osteoarthritis
Project from 2003 to 2004. Mean biomarker levels were estimated with linear regression. Proportional
and partial-proportional odds models were used to estimate associations. Interactions were tested with
likelihood ratio tests at a P-value < 0.10. Biomarkers were natural log (ln) transformed.
Results: Signiﬁcant differences in mean biomarker levels were found across severity of DSN for lnHA and
lnC2C and lnCTX-II across severity of both DSN and OST. Moderate-to-strong associations were found
between biomarkers of type II collagen and DSN, whereas associations with OST were weak. An asso-
ciation between lnHA and DSN was seen in women (adjusted odds ratio [aOR] ¼ 1.34 (95% conﬁdence
intervals (CI) 1.08, 1.65)) but no association among men (aOR ¼ 0.90 (95% CI 0.63, 1.26)). In Caucasians
there was a decreased association with NTX-I and OST (aOR ¼ 0.67 (95% CI 0.49, 0.91)) and no association
in African Americans (AAs) (aOR ¼ 1.06 (95% CI 0.76, 1.47)). There was a positive association of lnCOMP
with DSN among those with low back symptoms (aOR ¼ 1.82 (95% CI 1.02, 3.27)), but no association in
those without low back symptoms (aOR ¼ 0.65 (95% CI 0.35, 1.20)).
Conclusion: Joint metabolism biomarkers suggest biological differences in the pathologic process
involved in DSN and OST that may be gender (HA) and ethnicity (NTX-I) speciﬁc.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Intervertebral disc degeneration is a common condition with
prevalence estimates from community-based studies to be
between 50% and 64% (mean age >65 years).1e3 The degenerative: A.P. Goode, Department of
dical Center, 2200 West Main
-919-357-1039.
Goode), smarshall@unc.edu
Jordan_renner@med.unc.edu
rmer), carey@schsr.unc.edu
Joanne_jordan@med.unc.edu
s Research Society International. Pprocess is characterized by loss of water, aggrecan and types I and II
collagen,4,5 resulting in disc space narrowing (DSN) on plain ﬁlm
radiographs. Vertebral osteophytes (OST) are likely a response to
result from cartilage loss, biomechanical stress or trauma to the
annular insertion.6 Vertebral OST prevalence estimates from
community-based studies (mean age >65 years) range between
75% and 94%.1e3
Joint metabolism biomarkers, found in serum and urine, are
described according to the tissue(s) in which the markers are
abundant and with respect to the molecules they were developed
to identify. Type I collagen markers, such as the N-terminal telo-
peptide (NTX-I), reﬂect bone turnover or resorption. Type II
collagen markers, the C-terminal cross-linked telopeptide (CTX-II)ublished by Elsevier Ltd. All rights reserved.
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type II collagen degradation, whereas C-propeptide of type II pro-
collagen (CP-II) reﬂects cartilage synthesis.7 The non-aggrecan and
non-collagenous marker, such as cartilage oligomeric matrix
protein (COMP), reﬂect cartilage degradation but may also be found
in bone, ligaments, tendons and vascular smooth muscle.8 Hya-
luronic acid (HA) is a glycosaminoglycan that is indicative of oste-
oarthritis (OA) and synovial inﬂammation.7,9 These particular
biomarkers have been studied in OA of the hip10e12 and knee.13e19
Only CTX-II has been evaluated for an associationwith radiographic
changes in the lumbar spine.20,21
Our previous work with the Johnston County (JoCo) OA Project
has identiﬁed that the lumbar spine individual radiographic
features (IRFs) of DSN and OST differ substantially from one another
in prevalence suggesting a different pathophysiologic process
between the two. Furthermore, we found that the associations with
demographic, clinical and radiographic knee, hip and handOA differ
between these lumbar spine IRFs.22 Our primary objective for this
analysis was to compare a broad spectrum of serum (COMP, HA,
C2C, CP-II) and urine (NTX-I, CTX-II) biomarkers to determine if they
would reﬂect one or both of the OA-related processes represented
by lumbar spine DSN and OST. Our second objective was to deter-
mine if the associations of biomarkers with lumbar spine radiologic
features would differ among race and gender groups and according
to the presence of self-reported low back symptoms. We hypothe-
sized that these biomarkers would be independently associated
with lumbar spine DSN and OST above and beyond known associ-
ations with concomitant appendicular joint radiographic OA.
Methods and materials
Participants
Data for these cross-sectional analyses come from the JoCo OA
Project, an ongoing population-based study set in six rural town-
ships of JoCo, North Carolina. The purpose of the JoCo OA Project is to
determine the incidence, prevalence and progression of knee, hip,
hand, and spine OA. The sampling strategy and recruitmentmethods
used for the JoCo OA Project are described in detail elsewhere.23,24
Brieﬂy, baseline enrollment (1991e98) included civilian, non-
institutionalized, African American (AA) or Caucasian adult partici-
pants ages 45 years and older recruited by probability sampling. The
participants for these particular analyses come from 1,015 partici-
pants enrolled in the JoCo OA Project during cohort enrichment (T1*,
2003e04), following the ﬁrst follow-up (T1,1999e03) of participants
initially recruited from 1991 to 98. The T1* cohort enrichment aimed
to increase the sample for AAs and younger participants who were
lost over the follow-up period from the study initiation. As such,
participants at T1* were younger (mean age 59.3 vs 65.8 years) and
had a higher proportion of AAs (40% vs 28%) than those at T1; the
two groups did not differ according to gender.23
Radiographic evaluation
Of the 1,015 participants that underwent clinical examination,
840 had complete radiographic data for DSN and OST. Reasons for
not having lumbar spine radiographs included participant refusals
(n ¼ 6), women of reproductive age (<50 years of age) excluded by
protocol from having lumbar spine radiographs (n ¼ 132), partici-
pants exceeding radiographic table weight limit (n¼ 23) or missing
(n ¼ 6). Lateral lumbar spine ﬁlms were taken with the participant
lying on his/her left side. All lateral lumbar spine radiographs were
graded at each lumbar level by a single bone and joint radiologist
(JBR) without regard to participants’ biomarker levels. DSN and OST
were graded based upon the Burnett Atlas25 in a semi-quantitativefashion (0 ¼ none, 1 ¼ mild, 2 ¼ moderate and 3 ¼ severe). The
grading for OST was done for each superior and inferior aspect of
the anterior face of the lumbar vertebra.
Participants completed weight bearing posterior-anterior knee
radiography of both knees (n ¼ 979) with a Synaﬂexer (CCBR-
Synarc, San Francisco, CA) positioning device, and bilateral hip
radiography (n ¼ 830) with supine anterior-posterior pelvis radio-
graphs. Thepresence of a kneeprosthesis due to arthroplastywas the
primary reason for missing knee radiographic data. Women of
reproductive age (<50 years, n ¼ 132) were not subjected to pelvic
radiation; this accounted for themajorityofmissinghip radiographic
data. Posterior-anterior hand radiographs were available for 1,012
participants and were obtained with the beam focused on the third
metacarpal-phalangeal (MCP) joint; a total of 30 hand joints bilat-
erally were graded including: the distal interphalangeal (DIP),
proximal interphalangeal (PIP), metacarpal-phalangeal (MCP), car-
pometacarpal (CMC) and thumb interphalangeal (IP) andMCP joints.
All hip, knee andhand radiographswere read forKellgreneLawrence
(KeL)26 score by a single bone and joint radiologist (JBR). Inter-rater
and intra-rater reliability have been reported previously with
a weighted kappa of 0.86 and 0.89 for both the hip and knee.27 Hip
and knee OA, for these analyses, were deﬁned as a KeL score of 2e4
in at least one extremity. Hand OAwas deﬁned, similar to a previous
deﬁnition, as having at least onehandwith a KeL gradeof 2e4 in one
DIP joint and in at least two other interphalangeal joints or CMC
joints across both hands; participants were excluded on the basis of
anyMCPwith swellingof grade2orhigheron clinical examination.28
Biomarkers
The participants for this biomarkers study came from those
participants in T1* who also had serum and urine analyzed for joint
metabolism biomarkers as part of the sub-study of the JoCo OA
entitled the JoCo OA Metals Exposure Sub-study. This sub-study was
designed to consist of 1,700 consecutive individuals from T1* and
from the original cohort’s ﬁrst follow-up (T1) who returned for their
second follow-up (T2) in 2006e2008.29 The sample for the current
analysis included participants selected from T1* who had complete
biomarker analyses performed (n¼ 555). Urinary CTX-II hadmissing
values for 18 participants and urinary NTX-I had a single partic-
ipant missing value. There were no missing serum biomarker
values; however, some participants with biomarker values had
missing or unreadable (congenital defect or surgery) lumbar spine
radiographs. Therefore, the ﬁnal sample for these analyses consists of
547 participants that had both complete lumbar spine radiographs
and biomarker values from the original T1* enrollment (Fig. 1).
After collection at the clinic visit, blood and sera were separated
and stored on ice. Sera were frozen within 8 h of collection
at 20C, then transferred for long-term storage to an 86C
environment.
Demographic data
At the time of interview, the following data were collected: age;
body mass index (BMI) calculated from height measured without
shoes and weight measured with a balance beam scale, race
(Caucasian/AA); gender; and low back symptoms by asking
participants to answer “yes” or “no” to “On most days do you have
pain, aching or stiffness in your lower back?”
Deﬁnition of biomarkers
Biomarker analyses were conducted at the laboratory of
Dr. Virginia Kraus at Duke UniversityMedical Center. SerumHAwas
measured with the Hyaluronic Acid Test kit (Corgenix, Westmister,
Fig. 1. Figure ﬂow diagram of participants with complete radiographic and biomarker data for this analysis from the JoCo osteoarthritis Project new enrollment 2003e2004.
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5.7% and 7.0% inter-assay variability. Serum COMP was measured
using an in-house sandwich enzyme-linked immunosorbent assay
(ELISA). The reported precision is 5.8e6.6% intra-assay variability
and between 8.7% and 9.7% inter-assay variability. C2C was
measured with a competitive ELISA (Ibex, Montreal, CA). The
minimum detectable concentration of C2C is 7.3 ng/ml. Intra- and
inter-assay precisions are 2.41% and 9.49%, respectively. CP-II was
also measured with a competitive ELISA (Ibex, Montreal, CA). The
minimum detectable concentration is reported to be 35.1 ng/ml
and intra- and inter-assay precisions are 3.68% and 9.08%, respec-
tively. Urinary bone degradation markers, CTX-II (IDS, Boldon, UK)
and NTX-I (Osteomark, Princeton, NJ), were measured with
a competitive ELISA. The minimum detectable concentration of
urinary CTX-II is reported to be 0.20 ng/ml and the intra- and inter-
assay precisions are 5.86% and 9.97%, respectively. Urinary CTX-II
and NTX-I values were corrected for creatinine concentrations
measured by enzyme immunoassay (Quidel, San Diego, CA).
Deﬁnition of lumbar spine radiographic features
Since no universal method exists for coding IRF in the lumbar
spine, we utilized a summary procedure similar to a previous
study.9 For DSN, the scoring was based upon a 0e15 scale by
summing the values of grades 0e3 for each individual lumbar level.
For example, a participant would receive a score of 0 if there were
no DSN at a single level, a score of 1 if therewasmild DSN at a single
level, a score of 2 if there was moderate DSN at any one level or any
two levels of mild DSN and so forth; a maximum score of 15 is
possible representing a grade of 3 (severe DSN) at all ﬁve lumbar
levels. These scores were collapsed into four mutually exclusive
categories based upon the empirical distribution of severity grades
in order to reﬂect greater lumbar spine degenerative severity with
increasing scores (0 ¼ scores of 0, 1 ¼ scores of 1 and 2 combined,
2 ¼ scores of 3 and 4 combined and 3 ¼ scores of 5þ combined).
A similar scoring system was used for superior and inferior
(anterior) OST with values that could range from 0 to 30. These
scores were also collapsed into four mutually exclusive categories
(0¼ scores of 0e2,1¼ scores from 3 to 7 combined, 2¼ scores from
8 to 12 combined and 3 ¼ scores of 13þ).Statistical analysis
Each biomarker demonstrated a right skewed distribution, so
biomarkers were naturally log (ln) transformed. Descriptive
statistics were generated for each outcome in the form of means
and standard deviations (SDs) for continuous covariates and counts
and proportions for categorical covariates. Adjusted mean
biomarker levels were estimated using linear regression. Analysis
of variance was used to determine differences across categories of
severity and adjusted mean levels of each biomarker.
Due to ordinal nature of the outcome variables, proportional
odds (polytomous ordinal) logistic regression models were used for
all analyses, in which the outcomes met model ﬁt assumptions,
deﬁned as having a score test30 of P > 0.05 and with graphical
assessment of trends in the log-odds with incremental coding of
the outcomes.31,32 The proportional odds model assumes that the
odds ratios (ORs) are the same for all possible cut-points dichoto-
mizing the ordinal dependent variable (radiographic OA, for cate-
gories see Table I) into high vs low. For violations, an unconstrained
partial-proportional odds model has been recommended since it
relaxes the strict proportional odds assumption for only those
covariates not meeting the assumption.33 This model, therefore,
provides estimates for k  1 levels of the outcome, where k is equal
to the number of categories in the outcome, to best represent the
non-proportional effect across levels of the outcome when a single
estimate may not.31 An unconstrained partial-proportional odds
model is considered a “nested” version of the proportional odds
logistic regression model31; therefore, sensitivity analysis was
conducted between models where this approach was required.
Proportional ORs and their 95% conﬁdence intervals (CI) were
estimated from both models.
All models were adjusted for age, race, gender and BMI, as these
covariates have been associated with lumbar spine IRF and at least
some of our selected biomarkers in previous literature.20,21 The
confounding effect of the presence of knee, hip or hand OA was
explored using a backward stepwise deletion with a change in
estimate approach (difference in the model estimate once the co-
variate was removed).34 Therefore, knee, hip or hand OA were
retained in the ﬁnal models if there was a change in the estimate of
the logit of >5% between each of the biomarkers and either DSN or
Table I
Demographics and characteristics of the available 547 participants with lumbar spine radiographic data*
Score category (sample size) Disc space narrowingy OSTy
0 (n ¼ 231) 1e2 (n ¼ 194) 3e4 (n ¼ 84) 5þ (n ¼ 38) 0e2 (n ¼ 209) 3e7 (n ¼ 224) 8e12 (n ¼ 84) 13þ (n ¼ 30)
Gender
Men, n (%) 90 (43.1) 71 (36.4) 31 (15.7) 17 (6.2) 59 (28.4) 86 (41.4) 43 (20.1) 20 (9.6)
Women, n (%) 141 (41.7) 123 (34.0) 53 (14.8) 21 (8.1) 150 (44.3) 138 (40.7) 41 (12.1) 10 (3.0)
Race
AA, n (%) 99 (47.0) 70 (33.8) 24 (11.6) 14 (6.8) 94 (45.4) 77 (37.2) 25 (12.1) 11 (5.3)
Caucasian, n (%) 132 (38.8) 124 (36.5) 60 (17.7) 24 (7.1) 115 (33.8) 147 (43.2) 59 (17.4) 19 (5.6)
BMI, mean (SD) 29.9 (5.9) 29.5 (6.2) 30.8 (6.3) 30.6 (6.6) 29.4 (6.5) 30.0 (6.0) 31.2 (5.6) 32.7 (6.0)
Age, mean (SD) 58.4 (8.4) 61.6 (9.2) 64.3 (9.4) 67.6 (9.2) 59.1 (8.9) 62.5 (10.0) 67.0 (8.6) 70.0 (10.0)
Low back symptoms, n (%)
Present 99 (43.0) 90 (46.4) 49 (58.3) 27 (71.1) 95 (45.7) 108 (48.2) 47 (56.0) 15 (50.0)
Absent 131 (57.0) 104 (53.6) 35 (41.7) 11 (29.0) 113 (54.3) 116 (51.8) 37 (44.1) 15 (50.0)
Knee OA, n (%)
Present 49 (21.4) 54 (29.2) 32 (40.5) 18 (58.1) 40 (19.5) 64 (29.8) 33 (42.3) 16 (61.5)
Absent 180 (78.6) 131 (70.8) 47 (59.5) 13 (41.9) 165 (80.5) 151 (70.2) 45 (57.7) 10 (38.5)
Hip OA, n (%)
Present 52 (22.8) 41 (21.2) 18 (22.0) 16 (44.4) 48 (23.1) 50 (22.6) 18 (22.5) 12 (40.0)
Absent 176 (77.2) 152 (78.8) 64 (78.1) 20 (55.6) 160 (76.9) 171 (77.4) 62 (77.5) 18 (60.0)
Hand OA, n (%)
Present 41 (17.8) 50 (26.0) 38 (45.2) 25 (65.8) 39 (18.7) 66 (29.6) 34 (41.0) 15 (50.0)
Absent 190 (82.3) 142 (74.0) 46 (54.8) 13 (34.2) 170 (81.3) 157 (70.4) 49 (59.0) 15 (50.0)
Knee and Hip OA deﬁned as a KellgreneLawrence (KeL) grade of 2e4, Hand OA was deﬁned as having at least one extremity with a KeL grade of 2e4 in one DIP joint and
having at least 2 other interphalangeal joints or CMC joints across both hands.
* There are 18 missing values for CTX-II and 1 missing value for NTX-I.
y DSN and OST deﬁned by summing each participant’s lumbar spine grade of 0e3 to a score of 0e15 (DSN) 0e30 for superior and inferior vertebral OST.
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included the other radiographic feature. Pair-wise interaction
terms between each covariate and biomarker were used to assess
effect measure modiﬁcation. Interaction terms were retained in the
model if they had a likelihood ratio test P-value of <0.10. All vari-
ables were examined for collinearity using variance inﬂation
factors and tolerance values. No outliers were identiﬁed in the ﬁnal
models with sensitivity analyses utilizing leverage plots and
removal of potential outliers. All analyses were conducted in Stata
10 (Stata Corp, College Station, TX).
Results
Basic demographics, clinical characteristics, and presence of
knee, hip, or hand OA for each lumbar spine score category of DSN
and OST are summarized in Table I. Compared with men, women
were slightly more likely to have severe DSN. In contrast, menwere
more likely to have severe OST. The prevalence of low back symp-
toms increased monotonically across severity categories of DSN but
remained relatively constant across levels of OST severity. The
frequency of knee, hip and hand OA increased with increasing
severity of both DSN and OST. The mean age of participants was
higher in categories of more severe DSN and OST. Mean BMI
increased as severity of OST increased whereas remained relatively
constant across DSN severity.
Table II summarizes the adjusted geometric means and their
95% CI of biomarkers and DSN and OST. All models warranted
adjustment for knee OA whereas hip and hand OA did not result in
signiﬁcant confounding. The exception was for NTX-I, which
required no adjustment for any appendicular joint radiographic OA.
Differences in mean levels across severity of DSN were found for
lnHA and lnC2C (both adjusted for knee OA) but no differences
were observed across categories of OST. lnCTX-II demonstrated
differences in mean levels across both DSN and OST. No signiﬁcant
differences were found for adjusted mean levels of lnCP-II, lnCOMP
or lnNTX-I for DSN or OST.
Table III describes the adjusted associations between
biomarkers and both DSN and OST. Identical to the adjusted meanlevels, knee OAwarranted inclusion as an adjustment variable in all
models except with NTX-I. The strongest adjusted associations
were between DSN and lnC2C, lnCP-II and lnCTX-II. The relation
between lnHA and DSN did not meet model ﬁt assumptions
(P ¼ 0.001), indicating a violation of the proportional odds
assumption, with monotonically increasing ORs from 1.10 (95% CI
0.91, 1.33), 1.38 (95% CI 1.08, 1.78) and 2.18 (95% CI 1.45, 3.29) over
categories of DSN. The adjusted associations between biomarkers
and OST were weaker when compared to DSN. The estimate for
lnNTX-I was on the opposite side of the null for OST when
compared to DSN. lnCTX-II demonstrated the strongest association
with OSTand had a similar strength of association as DSN. However,
lnCTX-II did not meet proportional odds model ﬁt assumptions
(P ¼ 0.001) and the adjusted association was much stronger in the
most severe category of OST (OR ¼ 2.82 (95% CI 1.61, 4.94))
compared to categories of lesser severity OR ¼ 1.42 (95% CI 1.02,
1.99) and OR¼ 1.47 (95% CI 1.10,1.97), respectively. lnCOMPwas not
signiﬁcantly associated with either DSN or OST.
Most biomarkers did not demonstrate signiﬁcant differences
across race, gender or low back symptoms.
The association between lnNTX-I and OST was different across
race; we observed a signiﬁcant inverse association of lnNTX-1 and
OST (OR ¼ 0.67; 95% CI 0.49, 0.91) in Caucasians but not in AAs
(OR ¼ 1.06; 95% CI 0.76, 1.47). The association between lnNTX-I and
OST was also different by gender with a signiﬁcant inverse associa-
tion among women (OR ¼ 0.65; 95% CI 0.47, 0.89) but not among
men (OR ¼ 1.12; 95% CI 0.79, 1.60). The association between lnHA
and DSN had a signiﬁcant moderate association with women
(OR ¼ 1.34; 95% CI 1.08, 1.65) while men had no association
(OR¼ 0.90; 95% CI 0.63,1.26). Among thosewith low back symptoms
(n ¼ 265) there was a strong positive association with lnCOMP and
DSN (OR ¼ 1.82; 95% CI 1.02, 3.27) that was not observed in partic-
ipants without low back symptoms (OR ¼ 0.65; 95% CI 0.35, 1.20).
Discussion
Our study examined the relationship between a broad spectrum
of biomarkers and lumbar spine IRF within a large bi-racial
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Table III
Adjusted ORs with 95% CI, P-values and sample sizes for each biomarker by lumbar
DSN and anterior vertebral OST
Biomarker
(unit of measure)
Disc space narrowing OST
Adjusted OR
(95%CI)
P-value Adjusted OR
(95% CI)
P-value
lnCTX-II* (ng/mM Cr) 1.49 (1.15, 1.92) <0.01 1.33 (1.02, 1.72) 0.03
lnNTX-I (nMBCE/mMCr) 1.27 (1.01, 1.60) 0.04 0.82 (0.65, 1.05) 0.11
lnCP-II* (ng/ml) 1.68 (1.09, 2.61) 0.02 0.88 (0.56, 1.38) 0.58
lnC2C* (ng/ml) 1.77 (0.96, 3.24) 0.07 1.10 (0.60, 2.00) 0.76
lnCOMP* (ng/ml) 1.18 (0.76, 1.81) 0.46 1.08 (0.70, 1.67) 0.73
lnHA* (ng/ml) 1.21 (1.01, 1.45) 0.04 1.09 (0.91, 1.31) 0.34
C-terminal cross-linked telopeptide (CTX-II) measured in nanogram per millimole,
accounting for creatinine clearance. Cross-linked N-telopeptides (NTX-I) measured
in nanomole of bone equivalents accounting for creatinine clearance. C-Propeptide
(CP-II), Cleavage of type II collagen (C2C), COMP and HA all measured in nanograms
per milliliter. All models adjusted for age, race, gender, BMI and the other outcome.
* Adjusted for knee OA.
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several cases, the biomarkers reﬂected spine pathology in a bio-
logically plausible manner based on their known relative abun-
dance in spinal tissues. For instance, markers of type II collagen, the
most abundant protein in the nucleus pulposus,20 demonstrated
moderate-to-strong associations with DSN above and beyond
known associations with radiographic knee OA. In contrast, the
association between type II collagen biomarkers and OST were
weaker. This may be due to the expected lack of type II collagen in
a mature (bony) osteophyte since when the osteophyte is ﬁrst laid
down it is a chondrophyte with collagen II, then it undergoes
endochondral ossiﬁcation involving chondral anlage resorption
and remodeling into a bony osteophyte that would be visible and
gradable on a radiograph. In contrast, markers of less abundant
non-collagenous extracellular matrix components (lnHA and
lnCOMP) had weak associations with DSN but were responsive to
differences in gender and low back symptoms. Furthermore, lnHA
demonstrated increased adjusted mean levels with increasing
severity of DSN.
Two previous cross-sectional studies have examined the role of
CTX-II as a burden of disease biomarker in the spine.20,21 Our study
ﬁndings are generally consistent with both of these studies
regarding increasing levels of CTX-II with severity of DSN. However,
our results differ from Garnero and colleagues20 that found no
association between CTX-II and vertebral OST. Differences in
sample demographics may be one explanation for this difference.
We found that the most severe category of OST had a strong
association with CTX-II. This category of OST had a higher propor-
tion of men, who had more severe OST. This may help explain the
difference between our studies, since their study consisted of
women only. Other reasons may include coding scheme or grading
scale differences for the lumbar spine radiographic features
between studies.
Our ﬁndings indicate that associations between some, but not
all, lumbar spine IRF and biomarkers differ by subgroups of race and
gender. Previous studies have found that women are more likely to
have DSN compared to men.1,2 In this study, a moderate indepen-
dent association existed between lnHA and DSN in women.
Therefore, lnHA reﬂects this previously known gender difference in
DSN. In addition, our results indicate that there are signiﬁcant
differences in association across subgroups of both gender and race
between lnNTX-I and OST. In race and gender subgroups, lnNTX-I
reﬂected a decreased odds of OST. Women are known to have
less severe vertebral OST when compared to men22 and this could
be one explanation for the ﬁndings here with lnNTX-I. The differ-
ences in associationwe found between lnNTX-I and OST across race
A.P. Goode et al. / Osteoarthritis and Cartilage 20 (2012) 1286e1293 1291may also be explained by bone mineral content since racial differ-
ences in this process have been established.35 Although the race
and gender differences observed in this study are consistent with
differences in bone and spine structure, we were unable to
control for the established relationship between decreased bone
mineral density and lnNTX-I, which may confound our reported
associations.
Previous studies have found a relationship between biomarkers
and both hip and knee symptoms,36,37 and low back and sciatic
symptoms.38 We explored the relationship between biomarkers
and low back symptoms. Previous work by us and others has
revealed a modest association between low back symptoms and
DSN.1e3,22 Furthermore, the association between DSN and low back
symptoms has been found to increase with severity and number of
affected lumbar vertebral levels.1 Due to the multidimensional and
complex nature of low back pain, there are challenges to inter-
preting differences in associations of biomarkers with low back
symptoms. However, the association is noteworthy between
lnCOMP and DSN among those with and without low back symp-
toms. Only among participants with low back symptoms, was there
a strong direct association between lnCOMP and DSN. Therefore, it
is possible that lnCOMP reﬂects the ongoing degeneration of the
intervertebral disc reﬂected by DSN and resulting in associated
symptoms that have been reported with this process.
The confounding effect of concomitant peripheral joint OA may
differ based upon speciﬁc joint site and the biomarker analyzed.9
Interestingly, lnNTX-I, associated with DSN, demonstrated no
change in estimate when controlling for knee, hip or hand OA. This
suggests that these effects may work through a different pathologic
process. Hassett and colleagues39 reported strong associations
between both knee and hip OA progression and DSN while no
association was found with hand OA. In agreement, none of our
analyses were confounded by hand OA, but several required
adjustment for knee OA. The association between lnCOMP, lnCTX-II,
lnCP-II, lnC2C and lnHA with knee OA has been established in
previous literature40; therefore, it is not surprising that models
with these biomarkers required adjustment due to confounding by
the presence of knee OA. Hip OA was not a confounder in any
models, and this is consistent with our previous work that showed
that hip OA is not independently associated with lumbar spine
IRF.22 This further strengthens the argument that hip OA follows
a different etiologic process from that of the lumbar spine. These
ﬁndings are similar to the previous work by Kraus and colleagues,9
as they also found differences in the confounding effect of
concomitant peripheral joint OA and subsequent adjustment in
multivariate models.
A major strength of these analyses is that they were conducted
in a well-deﬁned, community-based population in which we
examined a broad spectrum of biomarkers across a balanced
representation of AAs and Caucasians and both men and women.
Moreover, we were able to analyze lumbosacral (LS) spine asso-
ciations with biomarkers in the context of concomitant knee, hip,
and hand radiographic OA. The primary limitation of this study
was its cross-sectional design; thus we could not address the
temporal relationship between the onset of serum biomarker
abnormalities and onset of OA; this can only be assessed using
longitudinal analyses. Our study population does not reﬂect the
general population in so far as our cohort contained a greater
proportion of AAs and had a younger mean age. We adjusted for
hip, knee, and hand OA to take into account their potential
contribution to biomarker levels; however, we did not control for
such things as medication use, liver function, and kidney function,
which may affect serum levels of biomarkers. All our variables had
attendant measurement error. Assuming independent, non-
differential errors, our estimates of associations would be anunderestimation of the true associations. Despite these limita-
tions, we conclude that our ﬁndings indicate that these bone and
joint biomarkers reﬂect differences in the process of degeneration
between DSN and OST. Furthermore, some of these biomarkers
may show differences in lumbar spine degeneration in both race
and gender subgroups and the presence of low back symptoms.
The ability of biomarkers to independently reﬂect metabolic
processes in the lumbar spine provides the impetus for future
studies to determine if biomarkers can also predict degenerative
changes in the lumbar spine.
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